You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. IGF OT IGF POTENTIAL COMMERCIALIZATION OF PROPRIETARY COMPOUND JR

    SBC: NAPROGENIX, INC.            Topic: NICHD

    alcohol

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  2. IGF OT IGF MULTIPLEXED HIGH CONTENT ASSAY TO MEASURE CELLULAR STRESS MECHANISMS FOR PREDICTIVE TOXICOLOGY STUDIES

    SBC: CAIRN BIOSCIENCES INC            Topic: NIDA

    The Contractor currently provides a high throughput assay platform that rapidly pinpoints compound mechanism of action and toxicity liabilities through its unique ability to monitor multiple facets of previously inaccessible biology in live cells in real time Through this SBIR Phase II contract the Contractor s existing platform will be applied to the development of a novel live cell multiplexed ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  3. IGF OT IGF SBIR PHASE II TOPIC DEVELOPMENT OF NOVEL THERAPEUTIC AGENTS THAT TARGET CANCER STEM CELLS

    SBC: LP Therapeutics Inc            Topic: NCI

    The goal of this project is to develop nanometer scale micelles to deliver high concentration of the chemotherapeutic drug daunorubicin DNR directly into acute myeloid leukemia AML stem cells LSCs and eradicate AML from the very root LSCs are a special group of leukemia cells that are relatively resistant to conventional doses of chemotherapy can regenerate more leukemia cells and cause le ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  4. IGF OT IGF SBIR PHASE II TOPIC BIOPSY OPTICAL SENSOR FOR IN SITU TISSUE ANALYSIS

    SBC: INTELLIGENT OPTICAL SYSTEMS, INC.            Topic: NCI

    Current methods for guiding cancer biopsies rely almost exclusively on X ray ultrasonic or magnetic resonance derived images While these are far more accurate than the age old technique of palpation all three still essentially characterize suspected lesions based only on tissue density

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  5. IGF OT IGF BLOOD TEST TO PREDICT RADIATION TOXICITY IN PATIENTS TREATED WITH RADIATION THERAPY

    SBC: Dxterity Diagnostics Inc            Topic: NCI

    In this Phase II project the goal is to continue development and validate the radiation toxicity RadTox diagnostic test We will also explore if gene expression in blood can be used to predict radiation sensitivity In our Phase I study gene expression based biomarkers were identified the DxDirect based assay was developed and the prototype predictor algorithm was developed In Phase II the ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  6. IGF OT IGF SBIR PHASE II TOPIC DEVELOPMENT OF NOVEL THERAPEUTIC AGENTS THAT TARGET CANCER STEM CELLS

    SBC: Cellerant Therapeutics, Inc.            Topic: NCI

    The effectiveness of current AML treatments is abysmal yielding only an overall year survival rate of and it has been hypothesized that the treatment may be more durable if leukemic stem cells LSC are eliminated IL RAP is a compelling target because it is expressed on LSC in majority of AML patients but not on healthy hematopoietic stem cells Also suppressing IL RAP expression in AML ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  7. IGF OT IGF SBIR PHASE II TOPIC SYNVIVO TUMOR A PHYSIOLOGICAL D MODEL OF THE TUMOR MICROENVIRONMENT

    SBC: CFD RESEARCH CORPORATION            Topic: NCI

    The overall goal of this project is to develop and validate a novel assay for mimicking the tumor microenvironment Our proposed assay will accurately model the tumor microenvironment encompassing a circulation in the vessels b transport across vessel walls and c tumors cultured in a dimensional environment In Phase I we successfully demonstrated our platform including multi cellular ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  8. DEFINING NORMAL TISSUE AND TUMOR BIOMARKERS OF RADIOSENSITIVITY TO BEST DIRECT TREATMENT

    SBC: MIRA DX, Inc.            Topic: NCI

    Radiation therapy has been a critical part of our approach to cure cancer for almost years While thetechnology for radiation delivery has dramatically improved the ability to personalize radiation treatmentbased on baseline genetic differences between patients has not yet been applied to direct therapy We have discovered that inherited germline DNA biomarkers disrupting microRNA regulato ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  9. SMARTPLATE TECHNOLOGY FOR ADVANCED CELLULAR STAC M

    SBC: CFD RESEARCH CORPORATION            Topic: NIDA

    This project will develop design fabricate test and demonstrate a novel SmartPlate Technology for Advanced Cell based Models STAC M The STAC M technology will be demonstrated for both current static culture and next generation cell based assays The proposed effort features a collaboration between CFD Research Corporation and Vanderbilt University and builds on several critical element ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  10. A minimally invasive catheter based treatment strategy to close ductus arteriosus in premature infants

    SBC: Inceptus Medical            Topic: NHLBI

    SummaryPremature infants with hemodynamically significant patent ductus arteriosus suffer increased mortality and significant morbidity A minimally invasive catheter based treatment strategy would be attractive Project GoalsThe goal of the project is to develop an implantable patent ductus arteriosus closure device to be safely delivered through the peripheral vasculature of a premature infant ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government